Business Context and Reporting Period
This Form 8-K was filed by Minerva Neurosciences, Inc. on January 12, 2022. The Company is incorporated in Delaware and its common stock trades on the Nasdaq Global Market under the symbol "NERV".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory listing matter.
Material Changes
On January 12, 2022, the Company received a deficiency letter from Nasdaq. The letter notified the Company that for the last 30 consecutive business days, the closing bid price of its common stock failed to maintain the minimum required price of $1.00 per share.
Outlook, Risks, and Contingencies
- Compliance Period: The Company has been granted 180 calendar days, until July 11, 2022, to regain compliance with the minimum bid price requirement.
- Trading Status: The deficiency letter does not result in immediate delisting. Common stock will continue to trade uninterrupted on the Nasdaq Global Market.
- Compliance Criteria: To regain compliance, the closing bid price must be at least $1.00 per share for a minimum of ten consecutive business days prior to July 11, 2022.
Investor Verification Checklist
- Verify the current closing bid price of NERV stock relative to the $1.00 threshold.
- Monitor the Company's progress toward achieving ten consecutive days of compliance before the July 11, 2022 deadline.
- Review subsequent filings for any updates on potential reverse stock splits or other capital structure changes intended to address the deficiency.